Qiagen (NYSE:QGEN) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Qiagen (NYSE:QGEN) announced its earnings results on Tuesday. The company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.58 by $0.03, Zacks reports. Qiagen had a return on equity of 14.77% and a net margin of 18.30%.The business had revenue of $533.00 million during the quarter, compared to the consensus estimate of $525.68 million. During the same period in the prior year, the business posted $0.57 earnings per share. Qiagen’s revenue was up 6.2% compared to the same quarter last year. Qiagen updated its FY 2025 guidance to 2.380-2.380 EPS and its Q4 2025 guidance to 0.600-0.600 EPS.

Qiagen Stock Performance

Shares of QGEN stock traded down $0.79 during mid-day trading on Thursday, reaching $43.26. The stock had a trading volume of 238,668 shares, compared to its average volume of 1,337,277. The firm’s 50 day simple moving average is $46.58 and its 200 day simple moving average is $46.47. The company has a quick ratio of 1.35, a current ratio of 1.61 and a debt-to-equity ratio of 0.25. Qiagen has a one year low of $37.63 and a one year high of $51.88. The firm has a market cap of $9.62 billion, a PE ratio of 25.53, a P/E/G ratio of 2.48 and a beta of 0.66.

Institutional Trading of Qiagen

Hedge funds have recently modified their holdings of the company. EverSource Wealth Advisors LLC lifted its position in shares of Qiagen by 226.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,598 shares of the company’s stock worth $125,000 after acquiring an additional 1,802 shares during the period. Osaic Holdings Inc. lifted its position in shares of Qiagen by 101.4% during the 2nd quarter. Osaic Holdings Inc. now owns 3,875 shares of the company’s stock worth $185,000 after buying an additional 1,951 shares during the period. Pitcairn Co. bought a new position in shares of Qiagen during the 2nd quarter worth approximately $208,000. Captrust Financial Advisors bought a new position in shares of Qiagen during the 2nd quarter worth approximately $221,000. Finally, Evergreen Capital Management LLC bought a new position in shares of Qiagen during the 2nd quarter worth approximately $246,000. Institutional investors own 70.00% of the company’s stock.

Wall Street Analyst Weigh In

QGEN has been the topic of a number of analyst reports. Cowen reissued a “hold” rating on shares of Qiagen in a report on Thursday, August 7th. Weiss Ratings reissued a “hold (c+)” rating on shares of Qiagen in a report on Wednesday, October 8th. UBS Group increased their price objective on Qiagen from $48.00 to $50.00 and gave the company a “neutral” rating in a report on Thursday, August 7th. Wall Street Zen raised Qiagen from a “hold” rating to a “buy” rating in a report on Saturday, November 1st. Finally, Barclays set a $53.00 target price on Qiagen and gave the company an “overweight” rating in a report on Thursday, October 2nd. Three research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat.com, Qiagen has a consensus rating of “Hold” and an average price target of $49.69.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.